Korean J Pediatr.  2010 Jun;53(6):688-693. 10.3345/kjp.2010.53.6.688.

Pulmonary hypertension in infants with bronchopulmonary dysplasia

• Kim GB

• KMID: 2280947
• DOI: http://doi.org/10.3345/kjp.2010.53.6.688

Abstract

An increase in the number of preterm infants and a decrease in the gestational age at birth have resulted in an increase in the number of patients with significant bronchopulmonary dysplasia (BPD) and secondary pulmonary hypertension (PH). PH contributes significantly to the high morbidity and mortality in the BPD patients. Therefore, regular monitoring for PH by using echocardiography and B-type natriuretic peptide (BNP) or N-terminal-proBNP must be conducted in the BPD patients with greater than moderate degree to prevent PH and to ensure early treatment if PH is present. In the BPD patients with significant PH, multi-modality treatment, including treatment for correcting an underlying disease, oxygen supply, use of diverse selective pulmonary vasodilators (inhaled nitric oxide, inhaled prostacyclins, sildenafil, and endothelin-receptor antagonist) and other methods, is mandatory.

Keyword

Pulmonary hypertension; Bronchopulmonary dysplasia; Vasodilator; Echocardiography; Brain natriuretic peptide

MeSH Terms

Bronchopulmonary Dysplasia
Dietary Sucrose
Echocardiography
Epoprostenol
Gestational Age
Humans
Hydrogen-Ion Concentration
Hypertension, Pulmonary
Infant
Infant, Newborn
Infant, Premature
Natriuretic Peptide, Brain
Nitric Oxide
Oxygen
Parturition
Piperazines
Prostaglandins I
Purines
Sulfones
Vasodilator Agents
Sildenafil Citrate
Dietary Sucrose
Epoprostenol
Natriuretic Peptide, Brain
Nitric Oxide
Oxygen
Piperazines
Prostaglandins I
Purines
Sulfones
Vasodilator Agents